Research Article

Antimicrobial and antibiofilm activities of desloratadine against multidrug-resistant Acinetobacter baumannii

Universidade Federal da Grande Dourados (UFGD), Laboratório de Pesquisa em Ciências da Saúde, Dourados, Mato Grosso do Sul, 79804-970, Brazil

Search for more papers by this author

Luana Rossato

https://orcid.org/0000-0003-0408-5294

Universidade Federal da Grande Dourados (UFGD), Laboratório de Pesquisa em Ciências da Saúde, Dourados, Mato Grosso do Sul, 79804-970, Brazil

Search for more papers by this author

Andressa LF Melo

https://orcid.org/0000-0001-6978-3726

Universidade Federal da Grande Dourados (UFGD), Laboratório de Pesquisa em Ciências da Saúde, Dourados, Mato Grosso do Sul, 79804-970, Brazil

Search for more papers by this author

Anna CM Valiente

https://orcid.org/0000-0003-3370-8577

Universidade Federal da Grande Dourados (UFGD), Laboratório de Pesquisa em Ciências da Saúde, Dourados, Mato Grosso do Sul, 79804-970, Brazil

Search for more papers by this author

Luiz F Plaça

https://orcid.org/0000-0001-7307-4105

Grupo de Pesquisa Nano & Photon, Instituto de Física, Universidade Federal do Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, 79070-900, Brazil

Search for more papers by this author

Heberton Wender

https://orcid.org/0000-0002-1417-3581

Grupo de Pesquisa Nano & Photon, Instituto de Física, Universidade Federal do Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, 79070-900, Brazil

Search for more papers by this author

Marcia SM Vaz

Universidade Federal da Grande Dourados (UFGD), Laboratório de Pesquisa em Ciências da Saúde, Dourados, Mato Grosso do Sul, 79804-970, Brazil

Search for more papers by this author

Suzana M Ribeiro‡

https://orcid.org/0000-0003-1781-3289

Colégio Militar de Curitiba, Curitiba, Paraná, 82800-030, Brazil

‡Authors contributed equally

Search for more papers by this author

Simone Simionatto‡

*Author for correspondence: Tel.: +55 679 9958 5355;

E-mail Address: simonesimionatto@ufgd.edu.br

https://orcid.org/0000-0003-2367-0915

Universidade Federal da Grande Dourados (UFGD), Laboratório de Pesquisa em Ciências da Saúde, Dourados, Mato Grosso do Sul, 79804-970, Brazil

‡Authors contributed equally

Search for more papers by this author

Published Online:10 Nov 2022https://doi.org/10.2217/fmb-2022-0085

View article

Abstract

Aim: The antimicrobial and antibiofilm activities of the antihistamine desloratadine against multidrug-resistant (MDR) Acinetobacter baumannii were evaluated. Results: Desloratadine inhibited 90% bacterial growth at a concentration of 64 μg/ml. The combination of desloratadine with meropenem reduced the MIC by twofold in the planktonic state and increased the antibiofilm activity by eightfold. Survival curves showed that combinations of these drugs were successful in eradicating all bacterial cells within 16 h. Scanning electron microscopy also confirmed a synergistic effect in imparting a harmful effect on the cellular structure of MDR A. baumannii. An in vivo model showed significant protection of up to 83% of Caenorhabditis elegans infected with MDR A. baumannii. Conclusion: Our results indicate that repositioning of desloratadine may be a safe and low-cost alternative as an antimicrobial and antibiofilm agent for the treatment of MDR A. baumannii infections.

Keywords:

References

1. Duarte S da CM, Stipp MAC, da Silva MM et al. Adverse events and safety in nursing care. Rev. Bras. Enferm. 68(1), 144–154 (2015).
Google Scholar
2. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin. Infect. Dis. 51(1), 79–84 (2010).
MedlineGoogle Scholar
3. Greene C, Vadlamudi G, Newton D, Foxman B, Xi C. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii. Am. J. Infect. Control 44(5), e65–71 (2016).
Medline CASGoogle Scholar
4. Al-Shamiri MM, Zhang S, Mi P et al. Phenotypic and genotypic characteristics of Acinetobacter baumannii enrolled in the relationship among antibiotic resistance, biofilm formation and motility. Microb. Pathog. 155, 104922 (2021).
Medline CASGoogle Scholar
5. Chapartegui-González I, Lázaro-Díez M, Bravo Z, Navas J, Icardo JM, Ramos-Vivas J. Acinetobacter baumannii maintains its virulence after long-time starvation. PLOS ONE 13(8), e0201961 (2018).
MedlineGoogle Scholar
6. Carvalhaes CG, Cayô R, Assis DM et al. Detection of SPM-1-producing Pseudomonas aeruginosa and class D β-lactamase-producing Acinetobacter baumannii isolates by use of liquid chromatography–mass spectrometry and matrix-assisted laser desorption ionization–time of flight mass spectrometry. J. Clin. Microbiol. 51(1), 287–290 (2013).
Medline CASGoogle Scholar
7. Maciel WG, da Silva KE, Croda J et al. Clonal spread of carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit. J. Hosp. Infect. 98(3), 300–304 (2018).
Medline CASGoogle Scholar
8. Nazzaro F, Fratianni F, De Martino L, Coppola R, De Feo V. Effect of essential oils on pathogenic bacteria. Pharmaceuticals 6(12), 1451–1474 (2013).
MedlineGoogle Scholar
9. World Health Organization. Antibacterial agents in preclinical development: an open access database (2019). www.who.int/publications-detail-redirect/WHO-EMP-IAU-2019.12
Google Scholar
10. Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 69(Suppl. 7), S565–S575 (2019).
Medline CASGoogle Scholar
11. Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The ‘old’ and the ‘new’ antibiotics for MDR Gram-negative pathogens: for whom, when, and how. Front. Public Health 7, 151 (2019).
MedlineGoogle Scholar
12. Roy R, Tiwari M, Donelli G, Tiwari V. Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence 9(1), 522–554 (2018).
Medline CASGoogle Scholar
13. Uchil RR, Kohli GS, Katekhaye VM, Swami OC. Strategies to combat antimicrobial resistance. J. Clin. Diagn. Res. 8(7), ME01–ME04 (2014).
MedlineGoogle Scholar
14. Cha Y, Erez T, Reynolds IJ et al. Drug repurposing from the perspective of pharmaceutical companies. Br. J. Pharmacol. 175(2), 168–180 (2018).
Medline CASGoogle Scholar
15. Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat. Microbiol. 4(4), 565–577 (2019).
Medline CASGoogle Scholar
16. Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens M-HDB. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov. Today 20(8), 1027–1034 (2015).
MedlineGoogle Scholar
17. Mercorelli B, Palù G, Loregian A. Drug repurposing for viral infectious diseases: how far are we? Trends Microbiol. 26(10), 865–876 (2018).
Medline CASGoogle Scholar
18. Cruz-Muñiz MY, López-Jacome LE, Hernández-Durán M et al. Corrigendum to ‘Repurposing the anticancer drug mitomycin C for the treatment of persistent Acinetobacter baumannii infections’ [International Journal of Antimicrobial Agents 49/1 (2017) 88–92]. Int. J. Antimicrob. Agents 52(6), 868 (2018).
Medline CASGoogle Scholar
19. Pawar AY. Combating devastating COVID-19 by drug repurposing. Int. J. Antimicrob. Agents 56(2), 105984 (2020).
Medline CASGoogle Scholar
20. Pushpakom S, Iorio F, Eyers PA et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18(1), 41–58 (2019).
Medline CASGoogle Scholar
21. Madhusoodanan J. Common allergy drug makes resistant bacteria vulnerable to antibiotics (2019). https://cen.acs.org/pharmaceuticals/antibiotics/Common-allergy-drug-makes-resistant/97/i24
Google Scholar
22. Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin. Ther. 31(5), 921–944 (2009).
Medline CASGoogle Scholar
23. Wang XY, Lim-Jurado M, Prepageran N, Tantilipikorn P, Wang DY. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Ther. Clin. Risk Manag. 12, 585–597 (2016).
Medline CASGoogle Scholar
24. Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin. Pharmacother. 11(5), 779–788 (2010).
Medline CASGoogle Scholar
25. da Silva KE, Maciel WG, Croda J et al. A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLOS ONE 13(12), e0209367 (2018).
Medline CASGoogle Scholar
26. Fehlberg LCC, Andrade LHS, Assis DM, Pereira RHV, Gales AC, Marques EA. Performance of MALDI-ToF MS for species identification of Burkholderia cepacia complex clinical isolates. Diagn. Microbiol. Infect. Dis. 77(2), 126–128 (2013).
Medline CASGoogle Scholar
27. Clinical & Laboratory Standards Institute C. Clinical & Laboratory Standards Institute: CLSI Guidelines (2020). https://clsi.org/
Google Scholar
28. Saputo S, Faustoferri RC, Quivey RG. A drug repositioning approach reveals that Streptococcus mutans is susceptible to a diverse range of established antimicrobials and nonantibiotics. Antimicrob. Agents Chemother. 62(1), e01674–17 (2017).
MedlineGoogle Scholar
29. Adusei EBA, Adosraku RK, Oppong-Kyekyeku J, Amengor CDK, Jibira Y. Resistance modulation action, time–kill kinetics assay, and inhibition of biofilm formation effects of plumbagin from Plumbago zeylanica Linn. J. Trop. Med. 2019, 1250645 (2019).
MedlineGoogle Scholar
30. Moody JA. Synergy testing: broth microdilution checkerboard and broth macrodilution methods. In: Clinical Microbiology Procedures Handbook. Eisenberg HD (Ed.). American Society for Microbiology, WA, USA, 5.18.1–5.18.23 (2007).
Google Scholar
31. Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48(W1), W488–W493 (2020).
Medline CASGoogle Scholar
32. Bardbari AM, Arabestani MR, Karami M et al. Highly synergistic activity of melittin with imipenem and colistin in biofilm inhibition against multidrug-resistant strong biofilm producer strains of Acinetobacter baumannii. Eur. J. Clin. Microbiol. Infect. Dis. 37(3), 443–454 (2018).
Medline CASGoogle Scholar
33. Kamaladevi A, Balamurugan K. Global proteomics revealed Klebsiella pneumoniae induced autophagy and oxidative stress in Caenorhabditis elegans by inhibiting PI3K/AKT/mTOR pathway during infection. Front. Cell. Infect. Microbiol. 7, 393 (2017).
MedlineGoogle Scholar
34. Stiernagle T. Maintenance of C. elegans. WormBook 10.1895/wormbook.1.101.1 (2006).
MedlineGoogle Scholar
35. Cheng Y-S, Sun W, Xu M et al. Repurposing screen identifies unconventional drugs with activity against multidrug resistant Acinetobacter baumannii. Front. Cell. Infect. Microbiol. 8, 438 (2018).
Medline CASGoogle Scholar
36. Chagas TPG, Carvalho KR, de Oliveira Santos IC, Carvalho-Assef APD, Asensi MD. Characterization of carbapenem-resistant Acinetobacter baumannii in Brazil (2008–2011): countrywide spread of OXA-23-producing clones (CC15 and CC79). Diagn. Microbiol. Infect. Dis. 79(4), 468–472 (2014).
Medline CASGoogle Scholar
37. Sennati S, Villagran AL, Bartoloni A, Rossolini GM, Pallecchi L. OXA-23-producing ST25 Acinetobacter baumannii: first report in Bolivia. J. Glob. Antimicrob. Resist. 4, 70–71 (2016).
MedlineGoogle Scholar
38. Young HL, Croyle C, Janelle SJ et al. Collaboration for containment: detection of OXA-23-like carbapenamase-producing Acinetobacter baumannii in Colorado. Infect. Control Hosp. Epidemiol. 39(10), 1273–1274 (2018).
MedlineGoogle Scholar
39. Gontijo AVL, Pereira SL, de Lacerda Bonfante H. Can drug repurposing be effective against carbapenem-resistant Acinetobacter baumannii? Curr. Microbiol. 79(1), 13 (2021).
MedlineGoogle Scholar
40. Attwood D, Udeala OK. Aggregation of antihistamines in aqueous solution: micellar properties of some diphenylmethane derivatives. J. Pharm. Pharmacol. 26(11), 854–860 (1974).
Medline CASGoogle Scholar
41. Dasgupta A, Dastidar SG, Shirataki Y. Antibacterial activity of artificial phenothiazines and isoflavones from plants. In: Bioactive Heterocycles VI: Flavonoids and Anthocyanins in Plants, and Latest Bioactive Heterocycles I. Motohashi N (Ed.). Springer, Berlin, Heidelberg, Germany, 67–132 (2008).
Google Scholar
42. Guth P, Spirtes M. The phenothiazinetranquilizers: biochemical and biophysical actions. Int. Rev. Neurobiol. 7, 231–278 (1964).
Medline CASGoogle Scholar
43. Molnár J, Király J, Mándi Y. The antibacterial action and R-factor-inhibiting activity by chlorpromazine. Experientia 31(4), 444–445 (1975).
Medline CASGoogle Scholar
44. Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat. Rev. Microbiol. 16(2), 91–102 (2018).
Medline CASGoogle Scholar
45. Perlmutter JI, Forbes LT, Krysan DJ et al. Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus. J. Med. Chem. 57(20), 8540–8562 (2014).
Medline CASGoogle Scholar
46. El-Banna TE-S, Sonbol FI, El-Aziz AAA, Al-Fakharany OM. Modulation of antibiotic efficacy against Klebsiella pneumoniae by antihistaminic drugs. Med. Microbiol. Diagn. 5(2), 1–13 (2016).
Google Scholar
47. El-Nakeeb M, Abou-Shleib H, Khalil A, Omar H, El-Halfawy O. In vitro antibacterial activity of some antihistaminics belonging to different groups against multi-drug resistant clinical isolates. Braz. J. Microbiol. 42(3), 980–991 (2011).
Medline CASGoogle Scholar
48. Cutrona N, Gillard K, Ulrich R, Seemann M, Miller HB, Blackledge MS. From antihistamine to anti-infective: loratadine inhibition of regulatory PASTA kinases in Staphylococci reduces biofilm formation and potentiates β-lactam antibiotics and vancomycin in resistant strains of Staphylococcus aureus. ACS Infect. Dis. 5(8), 1397–1410 (2019).
Medline CASGoogle Scholar
49. Chung PY. The emerging problems of Klebsiella pneumoniae infections: carbapenem resistance and biofilm formation. FEMS Microbiol. Lett. 363(20), fnw219 (2016).
MedlineGoogle Scholar
50. Ribeiro SM, Cardoso MH, Cândido E de S, Franco OL. Understanding, preventing and eradicating Klebsiella pneumoniae biofilms. Future Microbiol. 11(4), 527–538 (2016).
CASGoogle Scholar
51. Aguilar-Vega L, López-Jácome LE, Franco B et al. Antibacterial properties of phenothiazine derivatives against multidrug-resistant Acinetobacter baumannii strains. J. Appl. Microbiol. 131(5), 2235–2243 (2021).
Medline CASGoogle Scholar
52. Cobb DB, Watson WA, Fernández MC. High-dose loratadine exposure in a six-year-old child. Vet. Hum. Toxicol. 43(3), 163–164 (2001).
Medline CASGoogle Scholar
53. Simons FE. H1-receptor antagonists. Comparative tolerability and safety. Drug Saf. 10(5), 350–380 (1994).
Medline CASGoogle Scholar
54. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 56(Suppl. 65), 7–13 (2001).
MedlineGoogle Scholar

Vol. 18, No. 1

Metrics

Downloaded 365 times

History

Received 6 April 2022

Accepted 4 October 2022

Published online 10 November 2022

Published in print January 2023

Information

Keywords

Financial & competing interests disclosure

This work was partially funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq concession 437864/2018–9), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Universidade Federal da Grande Dourados (UFGD). M Mattos Vaz received a research grant from CAPES, and A Miltos Valiente and S Simionatto from CNPq. Sponsors did not take part in data collection, analysis and interpretation, nor in manuscript writing. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study was conducted with the approval of the Research Ethics Committee at the Universidade Federal da Grande Dourados (process no. 877.292/2014 and 4.014.325/2020).

PDF download